Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers

AAPS PharmSciTech

Volumn 14, Issue 1, 2013, Pages 38-44

  Zhou, Qi ^a   Qu, Li ^a   Gengenbach, Thomas ^b   Larson, Ian ^a   Stewart, Peter J ^a   Morton, David A V ^a  

^a MONASH UNIVERSITY   (Australia)

^b CSIRO   (Australia)

Author keywords

aerosolization; dry powder inhaler; magnesium stearate; mechanical dry powder coating; salbutamol sulphate

Indexed keywords

MAGNESIUM STEARATE; SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; BULK DENSITY; DRUG COATING; DRY POWDER INHALER; ENERGY; FLOW KINETICS; LASER DIFFRACTION; PRIORITY JOURNAL; SHEAR STRESS; SURFACE PROPERTY; X RAY PHOTOELECTRON SPECTROSCOPY;

AEROSOLS; DRY POWDER INHALERS; PARTICLE SIZE; PHOTOELECTRON SPECTROSCOPY; POWDERS; STEARIC ACIDS; SURFACE PROPERTIES;

EID: 84878600984     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9895-z     Document Type: Article

References (35)

1. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug-delivery to the respiratory-tract using dry powder inhalers. Int J Pharm. 1994;101(1-2):1-13.
2. Chan HK, Chew NYK. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev. 2003;55(7):793-805.
3. Patton JS, Platz RM. Penetration enhancement for polypeptides through epithelia. D. Routes of delivery - case-studies. 2. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev. 1992;8(2-3):179-96.
4. Kretchme N, Faber HK. Lactose intolerance. Nutr Rev. 1972;30(11):260.
5. Najafabadi AR, Gilani K, Barghi M, Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine. Int J Pharm. 2004;285(1-2):97-108.
6. Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005;110(1):130-40.
7. Raula J, Laehde A, Kauppinen EI. A novel gas phase method for the combined synthesis and coating of pharmaceutical particles. Pharm Res. 2008;25(1):242-5.
8. Chew NYK, Shekunov BY, Tong HHY, Chow AHL, Savage C, Wu J, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005;94(10):2289-300.
9. Sou T, Orlando L, McIntosh MP, Kaminskas LM, Morton DAV. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm. 2011;421(2):220-9.
10. Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res. 2006;23(5):931-40.
11. Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res. 2001;18(11):1570-7.
12. Adi H, Traini D, Chan HK, Young PM. The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci. 2008;97(7):2780-8.
13. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411-37.
14. Pfeffer R, Dave RN, Wei D, Ramlakhan M. Synthesis of engineered particulates with tailored properties using dry particle coating. Powder Technol. 2001;117(1-2):40-67.
15. Bose S, Bogner RH. Solventless pharmaceutical coating processes: a review. Pharm Dev Technol. 2007;12(2):115-31.
16. Zhou Q, Morton DAV. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv Drug Deliv Rev. 2012;64(3):275-84.
17. Zhou QT, Armstrong B, Larson I, Stewart PJ, Morton DAV. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur J Pharm Sci. 2010;40(5):412-21.
18. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 434.
19. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1-2):1-19. doi: 10.1016/j.ijpharm.2010.03.017.
20. Zhou QT, Qu L, Larson I, Stewart PJ, Morton DAV. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int J Pharm. 2010;394(1-2):50-9.
21. Zhou QT, Armstrong B, Larson I, Stewart PJ, Morton DAV. Improving powder flow properties of a cohesive lactose monohydrate powder by intensive mechanical dry coating. J Pharm Sci. 2010;99(2):969-81. doi: 10.1002/jps.21885.
22. Zhou QT, Denman JA, Gengenbach T, Das S, Qu L, Zhang H, et al. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J Pharm Sci. 2011;100(8):3421-30.
23. Schwedes J. Review on tester for measuring flow properties of bulk solids. Granul Matter. 2001;5:1-43.
24. Marriott C, MacRitchie HB, Zeng XM, Martin GP. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations. Int J Pharm. 2006;326(1-2):39-49.
25. Srichana T, Martin GP, Marriott C. A human oral-throat cast integrated with a twin-stage impinger for evaluation of dry powder inhalers. J Pharm Pharmacol. 2000;52(7):771-8. doi: 10.1211/0022357001774624.
26. Miller TA, York P. Pharmaceutical tablet lubrication. Int J Pharm. 1988;41(1-2):1-19.
27. Kippax P, Morton DAV. Aerosolization analysis. Drug Deliv Technol. 2008;8(1):53-8.
28. Coates MS, Fletcher DF, Chan HK, Raper JA. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22(6):923-32.
29. Castellanos A. The relationship between attractive interparticle forces and bulk behaviour in dry and uncharged fine powders. Adv Phys. 2005;54(4):263-376.
30. Edwards DA, Hanes J, Caponetti G, Hrkach J, BenJebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868-71. doi: 10.1126/science.276.5320.1868.
31. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Mimura K, Mamose D, et al. A new agglomerated KSR-592 beta-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J Control Release. 2003;88(1):23-33. doi: 10.1016/s0168-3659(02)00460-1.
32. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-27.
33. Zhou QT, Qu L, Gengenbach T, Denman JA, Larson I, Stewart PJ, et al. Investigation of the extent of surface coating via mechanofusion with varying additive levels and the influences on bulk powder flow properties. Int J Pharm. 2011;413(1-2):36-43.
34. Iida K, Hayakawa Y, Okamoto H, Danjo K, Luenberger H. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull. 2004;52(3):350-3. doi: 10.1248/cpb.52.350.
35. Young PM, Cocconi D, Colombo P, Bettini R, Price R, Steele DF, et al. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J Pharm Pharmacol. 2002;54(10):1339-44. doi: 10.1211/002235702760345400.